CEL-SCI Corporation Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by CEL-SCI Corporation (CEL-SCI) on May 21, 2025, with the earliest event reported on that date. The filing details the entry into a material definitive agreement for a public offering of common stock. The offering closed on May 23, 2025.
Key Financial Metrics
- Offering Size: 2,000,000 shares of common stock.
- Offering Price: $2.50 per share.
- Gross Proceeds: $5,000,000 (excluding the over-allotment option).
- Underwriting Discount: $0.175 per share.
- Over-Allotment Option: 45-day option to purchase up to 190,000 additional shares.
- Use of Proceeds: Funding continued development of Multikine, general corporate purposes, and working capital.
Note: This filing does not provide specific data on revenue, profit, cash flow, margins, debt, or liquidity metrics for the reporting period.
Material Changes
The primary material change is the execution of an underwriting agreement with ThinkEquity LLC and the subsequent closing of the equity offering. This transaction increases the company's share count and capital base. No other material changes to operations or financial status are detailed in this specific filing.
Guidance, Outlook, and Risks
Management intends to utilize the net proceeds to advance the development of Multikine and support working capital needs. The filing includes standard forward-looking statements cautioning that actual results may differ materially from projections. Risks and uncertainties are referenced in the Company's prospectus supplement filed on May 22, 2025, and its Annual Report on Form 10-K for the fiscal year ended September 30, 2024. The filing explicitly disclaims any obligation to update forward-looking statements.
Investor Verification Checklist
- Verify the final net proceeds after deducting all underwriting discounts and offering expenses.
- Confirm whether the 45-day over-allotment option for 190,000 shares was exercised by the underwriters.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and termination provisions.
- Examine the prospectus supplement (Rule 424(b)(5)) for detailed risk factors related to the Multikine development program.
- Check subsequent filings for the impact of this offering on the company's cash position and dilution metrics.